Brazil Pharma's IPO Set For Success

BMI View: Brazil Pharma's intial public offering (IPO) will be successful and we expect many institutional investors to purchase stakes in the company, which differentiates itself from the competition by selling lower-margin but higher-growth generic drugs. The firm is also present in less saturated geographic regions of the South American country.

To read the full article, please choose one of the following options: